Adriana Paladini

Dr. Adriana Paladini

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Stroke
Verified
Journal Article
Open access
ANAndrea Naldi
Andrea Naldi
Federico D'AgataFederico D'Agata
Federico D'Agata
GPGiovanni Pracucci
Giovanni Pracucci
VSValentina Saia
Valentina Saia
RCRoberto Cavallo
Roberto Cavallo
OCOn Behalf Of The Iretas Collaborators
On Behalf Of The Iretas Collaborators
BACKGROUND: The benefits and safety of mechanical thrombectomy (MT) in patients with prestroke disability, classified as modified Rankin Scale (mRS) score of 3 to 4, and anterior circulation stroke remain uncertain. This study aims to evaluate these factors using data from the Italian Registry of Endovascular Treatment in Acute Stroke. METHODS: We analyzed data collected between 2015 and 2021, comparing functional outcomes (mRS), symptomatic intracerebral hemorrhage, and recanalization rates (Thrombolysis in Cerebral Infarction) at 90 days post-MT in patients with prestroke mRS score of 3 to 4 versus 0 to 2. A good outcome was defined as no change in the mRS score from baseline. Subgroup analysis was stratified by age. RESULTS: A total of 11.411 (96%) patients with prestroke mRS score of 0 to 2 and 477 (4%) patients with prestroke mRS score of 3 to 4 were included. Compared with patients with a baseline mRS score 0 to 2, those with mRS score 3 to 4 were older (82 versus 75 years; P <0.001) and predominantly female (71.7% versus 53%; P <0.001). The maintenance of the same mRS score after MT was observed in 100 (23.3%) patients with prestroke mRS score 3 to 4, compared with 2332 (22.1%) patients with mRS score 0 to 2 ( P =0.556). Mortality was significantly higher in the mRS score 3 to 4 group (n=159 [37.1%] versus n=1939 [18.4%]; P <0.001). Successful recanalization (Thrombolysis in Cerebral Infarction score ≥2b) was lower in the mRS score 3 to 4 group (n=333 [71.6%] versus n=8706 [77.7%]; P =0.002), while no significant differences in symptomatic intracerebral hemorrhage were found. The benefit of MT was maintained in patients aged 80 to 85 and over 85 years with prestroke mRS score 3 to 4, although mortality remained higher. CONCLUSIONS: Our data suggest that prestroke disability does not imply less chance of returning to prestroke conditions after MT, even in octogenarians, despite higher mortality and lower recanalization rate. More data are warranted to better understand the benefit of MT in this subgroup of patients.

9 June 2025 in Interventional Neuroradiology
Verified
Journal Article
Open access
ECElisa Francesca Maria Ciceri
Elisa Francesca Maria Ciceri
ELEmilio Lozupone
Emilio Lozupone
MMMatteo Milani
Matteo Milani
MPMariangela Piano
Mariangela Piano
VCValentina Caldiera
Valentina Caldiera
CRChiara Riccietti
Chiara Riccietti
Background: The introduction of flow diverters (FDs) has revolutionized the treatment of complex intracranial aneurysms; subsequent surface modifications have extended their indications to ruptured, bifurcation, and distal aneurysms. The aim of this study is to assess the real-world feasibility and safety of HPC surface-modified devices in the treatment of ruptured and unruptured aneurysms. Methods: This independent, multicenter, prospective observational study evaluated the outcomes of patients treated with implanted Phenox p64 or p48 MW-HPC-FDs between 2020 and 2022. The sub-analysis of the procedures, complications (clinical and technical), and additional treatment requirements assessed the devices’ feasibility and safety in the peri-procedural period. Results: One hundred and forty aneurysms (35% ruptured and 65% unruptured) were treated in 140 patients (37 females and 103 males) using 153 HPC-FDs (111 p64 and 42 p48): 100 aneurysms were saccular (71%), 22 dissecting (16%), 13 fusiform (9%), and five blister-like (3.6%). The successful deployment rate was 97.9%. The overall peri-procedural mortality rate was 9%, including three device-related deaths (2.2%); the overall morbidity rate was 12.1% (6.4% severe, 3.6% mild, and 2.1% asymptomatic adverse events); 4.4% of the clinical adverse events were certainly device related, and 2.2% were probably device related. Conclusions: The use of p64 and p48 HPC-FDs is highly feasible and acceptably safe, although further data are needed to assess the impact of the coating on safety in emergency and elective procedures.

18 December 2025 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
ELEmilio Lozupone
Emilio Lozupone
RBRoland Barbante
Roland Barbante
GBGiovanni Barchetti
Giovanni Barchetti
MIMikel Terceño Izaga
Mikel Terceño Izaga
VVVictor Vazquez-Añón
Victor Vazquez-Añón
APAdriana Paladini
Adriana Paladini

8 June 2026 in Neurosurgery
Verified
Journal Article
Closed access
MPMariangela Piano
Mariangela Piano
AVAlessio Vitiello
Alessio Vitiello
ELEmilio Lozupone
Emilio Lozupone
PRPaolo Remida
Paolo Remida
CCConcetto Cristaudo
Concetto Cristaudo
LVLuca Valvassori
Luca Valvassori
BACKGROUND AND OBJECTIVE: Flow diverter devices have revolutionized the treatment of intracranial aneurysms, but evidence on newer-generation devices remains limited. The Surpass Evolve (SE) was designed to improve deliverability and vessel wall apposition compared with its predecessors. This registry aimed to evaluate the feasibility, safety, and efficacy of SE in a large, real-world multicenter cohort with long-term follow-up. METHODS: Between May 2019 and December 2022, 275 consecutive aneurysms in 272 patients were treated with the SE flow diverter across 28 Italian centers. Clinical and imaging follow-up was completed by January 2024. Mid-term (≤6 months) and long-term (≤24 months) follow-ups, including clinical assessment, angiography, and cross-sectional imaging (computed tomography/magnetic resonance), were systematically collected and independently reviewed by a central Core Lab. RESULTS: The mean maximum diameter of the aneurysm was 11.2 mm, and the mean neck size was 5.4 mm. A total of 258 aneurysms were unruptured (93.8%), and 17 (6.2%) were ruptured. The majority arose from the anterior circulation (87.6%), with 12.4% in the posterior circulation. Device deployment was unsuccessful in 5/278 procedures (1.8%), and misdeployment occurred in 28/278 (10%). The overall device-related mortality was 0.7%, and the morbidity was 5.4%. At mid-term follow-up, complete or near-complete occlusion was achieved in 66% of aneurysms, increasing to 92% at long-term. According to mass criteria, 82% of aneurysms were considered cured, whereas sac enlargement occurred in 0.5% and 17% remained unchanged in volume. CONCLUSION: Our experience using SE for endovascular treatment of intracranial aneurysms showed a high safety and efficacy profile, substantially equivalent to that of the other flow diverter devices commonly used.

FCFlavio Cassano
Flavio Cassano
GTGiovanni Leo Tomacelli
Giovanni Leo Tomacelli
CCCosta Maria Carmela
Costa Maria Carmela
BGBesozzi Gianluca
Besozzi Gianluca
RTRizzo Tiziana
Rizzo Tiziana
GSGuglielmo Sticchi
Guglielmo Sticchi
Background: Conventional CT–dacryocystography (CT-DCG) requires canalicular cannulation and forced contrast injection, which may distort anatomy and cause discomfort. This study describes a non-cannulated CT-DCG protocol using dropwise iodixanol 320 instillation designed to simulate physiological tear drainage. Methods: We retrospectively reviewed 80 patients (25 males, 55 females; mean age 64.3 ± 8.9 years) with suspected nasolacrimal duct obstruction. Iodixanol 320 was instilled at 2 drops/min for 10 min without cannulation. Imaging was performed on a low-dose 128-slice CT system with multiplanar reconstructions. Lacrimal patency, obstruction site, and patient discomfort (10-point VAS) were evaluated by a blinded radiologist. Results: Adequate contrast opacification was achieved in all cases. Obstruction was detected in 70/80 (87.5%) patients. Mean patient discomfort was 2.1 ± 1.3 VAS scale, lower than the values reported in the literature for conventional CT-DCG. No adverse reactions occurred. Conclusions: Non-cannulated CT-DCG with dropwise iodixanol instillation is a feasible and well-tolerated imaging technique that provides high diagnostic yield while preserving physiological tear flow. Further prospective, comparative studies are warranted to validate these findings.